Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR2 N549K FIIN-1 endometrial carcinoma sensitive detail...
FGFR2 K310R FGFR2 N549K FIIN-1 endometrial carcinoma sensitive detail...
FGFR2 wild-type FIIN-1 endometrial carcinoma resistant detail...
FGFR2 S252W RO4987655 endometrial carcinoma decreased response detail...
FGFR2 N549K RO4987655 endometrial carcinoma no benefit detail...
FGFR2 K310R FGFR2 N549K RO4987655 endometrial carcinoma no benefit detail...
FGFR2 N549K RO5126766 endometrial carcinoma no benefit detail...
FGFR2 K310R FGFR2 N549K RO5126766 endometrial carcinoma no benefit detail...
FGFR2 S252W Selumetinib endometrial carcinoma decreased response detail...
FGFR2 N549K Selumetinib endometrial carcinoma no benefit detail...
FGFR2 K310R FGFR2 N549K Selumetinib endometrial carcinoma no benefit detail...
FGFR2 S252W RO5126766 endometrial carcinoma sensitive detail...
PIK3CA R88L PIK3CA E453del PIK3CA T1052K PTEN loss PTEN mut Copanlisib endometrial carcinoma sensitive detail...
FGFR2 S252W GSK3052230 endometrial carcinoma sensitive detail...
MLH1 mutant N/A endometrial carcinoma not applicable detail...
MSH6 mutant N/A endometrial carcinoma not applicable detail...
PIK3CA mutant Copanlisib endometrial carcinoma no benefit detail...
TP53 mutant Adavosertib endometrial carcinoma predicted - sensitive detail...
PTEN negative Olaparib endometrial carcinoma no benefit detail...
PTEN negative Buparlisib endometrial carcinoma sensitive detail...
PTEN negative Buparlisib + Olaparib endometrial carcinoma sensitive detail...
PTEN del Olaparib endometrial carcinoma no benefit detail...
PTEN del Buparlisib endometrial carcinoma sensitive detail...
PTEN del Buparlisib + Olaparib endometrial carcinoma sensitive detail...
MLH1 negative Pembrolizumab endometrial carcinoma sensitive detail...
MSH6 negative Pembrolizumab endometrial carcinoma sensitive detail...
MSH6 negative Dostarlimab-gxly endometrial carcinoma sensitive detail...
MLH1 negative Dostarlimab-gxly endometrial carcinoma sensitive detail...
MLH1 negative Nivolumab endometrial carcinoma sensitive detail...
MSH6 negative Nivolumab endometrial carcinoma sensitive detail...
MLH1 negative Avelumab endometrial carcinoma sensitive detail...
MSH6 negative Avelumab endometrial carcinoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00492778 Phase II Cisplatin Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Active, not recruiting USA | CAN 0
NCT00996892 Phase I Cobimetinib + Pictilisib Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors Terminated USA 0
NCT01174121 Phase II Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer Recruiting USA 0
NCT01440998 Phase I Carboplatin + Dasatinib + Paclitaxel Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Completed USA 0
NCT01504126 Phase I Propranolol Beta-Blocker / Ovarian Completed USA 0
NCT01888562 Phase I Ponatinib Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma Withdrawn 0
NCT01935973 Phase II Trametinib Trametinib + Uprosertib Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed USA 0
NCT02059265 Phase II Dasatinib Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer Terminated USA 0
NCT02065687 Phase III Carboplatin + Metformin + Paclitaxel Carboplatin + Paclitaxel Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Unknown status USA 0
NCT02117817 Phase I Buparlisib + Nab-paclitaxel Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer Withdrawn 0
NCT02228681 Phase II Tamoxifen Medroxyprogesterone Everolimus + Letrozole Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer Active, not recruiting USA 0
NCT02397083 Phase II Everolimus Phase II Study of Intrauterine Device (IUD) Alone or in Combination With Everolimus in Endometrial Cancer Active, not recruiting USA 0
NCT02454972 Phase II Lurbinectedin Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors Completed USA | ITA | GBR | FRA | ESP | DEU | BEL 2
NCT02549209 Phase II Carboplatin + Paclitaxel + Pembrolizumab Pembro/Carbo/Taxol in Endometrial Cancer Completed USA 0
NCT02549989 Phase II LY3023414 Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer Completed USA 0
NCT02558348 Phase Ib/II Anlotinib Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001) Terminated USA 0
NCT02611024 Phase Ib/II Irinotecan + Lurbinectedin Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors Recruiting USA | ITA | FRA | ESP | DEU 1
NCT02628067 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Recruiting USA | NLD | ITA | FRA | ESP | DEU | CAN | AUS 15
NCT02725268 Phase II Paclitaxel Sapanisertib Sapanisertib + Serabelisib Phase 2 Study of MLN0128, Combination of MLN0128 With MLN1117, Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer Completed USA | NLD | ITA | GBR | ESP | DEU | CAN | BEL | AUS 1
NCT02807844 Phase Ib/II MCS110 + Spartalizumab Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies Completed USA | ITA | FRA | ESP | DEU | BEL 5
NCT02977195 Phase I NP137 First in Human Evaluation of Safety, Pharmacokinetics, and Clinical Activity of a Monoclonal Antibody Targeting Netrin 1 in Patients With Advanced/Metastatic Solid Tumors (NP137) Completed FRA 0
NCT03008408 Phase II Everolimus + Letrozole + Ribociclib Phase II Ribociclib, Everolimus and Letrozole in Endometrial Cancer Active, not recruiting USA 0
NCT03015129 Phase II Durvalumab Durvalumab + Tremelimumab A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer Completed USA 0
NCT03076372 Phase I MM-310 A Study Evaluating MM-310 in Patients With Solid Tumors Unknown status USA 0
NCT03077698 Phase II Megestrol acetate + Sodium cridanimod An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer Terminated USA 0
NCT03138408 Phase I SC-004 Budigalimab + SC-004 SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers Terminated USA 0
NCT03192059 Phase II Aspirin + Cyclophosphamide + Pembrolizumab + Vitamin D Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine Cancer (PRIMMO) Completed BEL 0
NCT03212404 Phase I Cosibelimab Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers Recruiting NZL | FRA | ESP | AUS 5
NCT03241745 Phase II Nivolumab A Study of Nivolumab in Selected Uterine Cancer Patients Completed USA 0
NCT03319628 Phase I XMT-1536 First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b Active, not recruiting USA 0
NCT03367741 Phase II Cabozantinib + Nivolumab Nivolumab Cabozantinib and Nivolumab in Treating Patients With Advanced, Recurrent or Metastatic Endometrial Cancer Active, not recruiting USA | CAN 0
NCT03476798 Phase II Bevacizumab + Rucaparib Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium Completed USA 0
NCT03517449 Phase III Lenvatinib + Pembrolizumab Paclitaxel Doxorubicin Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) Active, not recruiting USA | NZL | ITA | GBR | FRA | ESP | DEU | CAN | AUS 12
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Completed USA 0
NCT03526432 Phase II Atezolizumab + Bevacizumab Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer Active, not recruiting USA 0
NCT03603184 Phase III Atezolizumab + Carboplatin + Paclitaxel Carboplatin + Paclitaxel Atezolizumab Trial in Endometrial Cancer - AtTEnd (AtTEnd) Active, not recruiting NZL | ITA | GBR | ESP | DEU | AUT | AUS 4
NCT03660826 Phase II Olaparib Cediranib + Olaparib Olaparib and Cediranib Maleate in Treating Patients With Recurrent, Refractory, or Metastatic Endometrial Cancer Active, not recruiting USA | CAN 0
NCT03752398 Phase I Izuralimab A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) Active, not recruiting USA 0
NCT03836157 Phase II Bevacizumab + Mirvetuximab Soravtansine Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer Withdrawn USA 0
NCT03849469 Phase I Pembrolizumab + XmAb22841 XmAb22841 A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) Completed USA 0
NCT03884101 Phase III Carboplatin + Paclitaxel Lenvatinib + Pembrolizumab Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) Active, not recruiting USA | ITA | GBR | ESP | DEU | CAN | BEL | AUT | AUS 13
NCT03909152 Phase II Onapristone Anastrozole + Onapristone A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone Active, not recruiting USA 0
NCT03914612 Phase III Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer Active, not recruiting USA | CAN 3
NCT03917381 Phase Ib/II GEN1046 GEN1046 Safety Trial in Patients With Malignant Solid Tumors Active, not recruiting USA | ITA | ESP 7
NCT03926936 Phase II Fulvestrant FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study (FUCHSia) Recruiting BEL 0
NCT03932409 Phase I Pembrolizumab Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer (FIERCE) Recruiting USA 0
NCT03955978 Phase I Dostarlimab-gxly TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer Recruiting USA 0
NCT04014530 Phase Ib/II Pembrolizumab + PTC124 Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study (ATAPEMBRO) Recruiting NLD 0
NCT04065269 Phase II Ceralasertib + Olaparib Ceralasertib ATr Inhibitor in Combination With Olaparib in Gynaecological Cancers With ARId1A Loss or no Loss (ATARI) Unknown status GBR 0
NCT04106414 Phase II Nivolumab Linrodostat + Nivolumab Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment Active, not recruiting USA 0
NCT04205630 Phase II Trastuzumab Duocarmazine SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma Completed USA 6
NCT04235101 Phase I Niraparib + Trastuzumab Duocarmazine Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors Completed NLD | GBR | BEL 0
NCT04251416 Phase II Sacituzumab govitecan-hziy A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma Recruiting USA 0
NCT04269200 Phase III Durvalumab Durvalumab + Olaparib Carboplatin + Durvalumab + Paclitaxel Carboplatin + Durvalumab + Olaparib + Paclitaxel Carboplatin + Paclitaxel Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer (DUO-E) Active, not recruiting USA | ESP | DEU | CAN | BEL | AUS 16
NCT04282018 Phase Ib/II BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab Recruiting AUS 1
NCT04450901 Phase I YBL-006 Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors Active, not recruiting AUS 2
NCT04469764 Phase II Abemaciclib + Anastrozole Abemaciclib + Letrozole Abemaciclib Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer Recruiting USA 0
NCT04486352 Phase Ib/II Atezolizumab + Talazoparib Atezolizumab + Ipatasertib Atezolizumab + Bevacizumab A Study of Targeted Agents With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer (EndoMAP) Recruiting USA 0
NCT04513665 Phase II ZW25 ZW25 in Women With Endometrial Cancers Completed USA 0
NCT04634877 Phase III Carboplatin + Paclitaxel Cisplatin + Paclitaxel Carboplatin + Docetaxel Cisplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Docetaxel + Pembrolizumab Cisplatin + Docetaxel Carboplatin + Docetaxel + Pembrolizumab Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT 19
NCT04652076 Phase Ib/II Carboplatin + NP137 + Paclitaxel Trevatide + Pembrolizumab NP137 + Pembrolizumab Carboplatin + NP137 + Paclitaxel Carboplatin + Paclitaxel GYNecological Cancers Treated With NETrin mAbs in Combination With Chemotherapy and /or Pembrolizumab (GYNET) Recruiting FRA 0
NCT04678908 Phase I HB0025 A Study of Injection HB0025 in Patients With Advanced Solid Tumors Recruiting USA 1
NCT04719273 Phase II Anastrozole + Onapristone Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer Active, not recruiting USA 0
NCT04795661 Phase II Pembrolizumab Immunotherapy in MSI/dMMR Tumors in Perioperative Setting. (IMHOTEP) Active, not recruiting FRA 0
NCT04906382 Phase I Carboplatin + Paclitaxel + Tislelizumab Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer Terminated USA 0
NCT05032040 Phase II XmAb20717 A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies Recruiting USA 0
NCT05036681 Phase II Futibatinib + Pembrolizumab A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma Recruiting USA 0
NCT05043714 Phase I NG-641 + Nivolumab Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours (NEBULA) Recruiting USA | GBR 0
NCT05069935 Phase I Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors Terminated USA 0
NCT05086692 Phase Ib/II MDNA11 + Pembrolizumab A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) Recruiting USA | CAN | AUS 1
NCT05143970 Phase I IPH5301 IPH5301 + Paclitaxel + Trastuzumab A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (CHANCES) Recruiting FRA 0
NCT05154487 Phase II Alpelisib + Fulvestrant A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer Recruiting USA 0
NCT05156268 Phase II Olaparib + Pembrolizumab A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma Recruiting USA 0
NCT05173987 Phase III Cisplatin + Docetaxel Carboplatin + Docetaxel Carboplatin + Paclitaxel Cisplatin + Paclitaxel Pembrolizumab Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) Active, not recruiting USA | NZL | NLD | ITA | GBR | ESP | DEU | CAN | BEL | AUS 17
NCT05194072 Phase I SGN-B7H4V A Study of SGN-B7H4V in Advanced Solid Tumors Recruiting USA | ITA | GBR | ESP | DEU | CAN 0
NCT05255653 Phase II Olaparib Medroxyprogesterone Carboplatin Megestrol acetate Paclitaxel Cisplatin Durvalumab Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) Recruiting NLD | GBR | FRA | CAN 0
NCT05269381 Phase I Cyclophosphamide + Neoantigen peptide vaccine + Pembrolizumab + Sargramostim Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA) Recruiting USA 0
NCT05300048 Phase I Serabelisib Nab-paclitaxel + Serabelisib Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations Active, not recruiting USA 0
NCT05542407 Phase I Atezolizumab + ONC201 ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer Recruiting USA 0
NCT05564377 Phase II Selumetinib Binimetinib + Fulvestrant Binimetinib + Palbociclib Nilotinib + Paclitaxel Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin Panitumumab + Sotorasib Binimetinib Fulvestrant Olaparib Olaparib + Selumetinib Alpelisib + Olaparib Neratinib Neratinib + Palbociclib Fluorouracil + Leucovorin + Oxaliplatin Ipatasertib + Paclitaxel Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial Recruiting USA 1
NCT05603910 Phase I Lenvatinib + Pembrolizumab Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma Recruiting USA 0
NCT05714553 Phase Ib/II Docetaxel + Leucovorin + NUC-3373 Leucovorin + NUC-3373 + Pembrolizumab NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours Recruiting GBR 0
NCT05795595 Phase Ib/II CTX131 A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors Recruiting USA 0
NCT05904496 Phase I BGB-30813 BGB-30813 + Tislelizumab A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-30813 Recruiting USA | ESP | AUS 0
NCT05949424 FDA approved Lenvatinib Olaparib Pazopanib Palbociclib Sunitinib OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults (OPTI-DOSE) Not yet recruiting NLD 0
NCT05958199 Phase I NPX267 Treatment With NPX267 for Subjects With Solid Tumors Known to Express HHLA-2 Recruiting USA 0
NCT06046274 Phase II GEN1046 + Pembrolizumab GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer Withdrawn USA | ITA | ESP | BEL 2
NCT06132958 Phase III Paclitaxel Doxorubicin SKB264 MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) Recruiting USA | NLD | ITA | GBR | FRA | ESP | CAN | BEL | AUT | AUS 15
NCT06172478 Phase II Patritumab deruxtecan A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting 0